Armour Thyroid Monitoring Schedule: Labs & Exams

Armour Thyroid is a porcine-derived desiccated thyroid product that supplies both levothyroxine (T4) and liothyronine (T3), distinguishing it from synthetic T4-only formulations. The product carries FDA approval for hypothyroidism treatment and requires a prescription. Since Armour Thyroid provides preformed T3 rather than depending exclusively on peripheral conversion from T4, TSH-only monitoring may overlook relevant clinical findings. The monitoring framework presented here aligns with established endocrine principles for dual T4/T3 replacement and does not replace the personalized approach developed by the treating physician.

The central claim of this page: on Armour Thyroid, TSH alone is an incomplete monitoring tool because the T3 component suppresses TSH more than an equivalent thyroid status on T4-only therapy would, so free T3 needs to be checked alongside TSH and free T4, with blood drawn fasting and before the day's dose to avoid a false peak reading. This reflects general principles in American Thyroid Association (ATA) and AACE/ACE hypothyroidism guidance around combination T4/T3 therapy, not a claim specific to any single trial, and exact numeric thresholds should be individualized by the prescriber rather than applied mechanically.

What is established, what is plausible, and what is not established

Established: Desiccated thyroid contains both T4 and T3, T3 has a much shorter half-life than T4, and TSH can run lower on combination therapy than on levothyroxine alone at a comparable clinical thyroid status. Guideline bodies recommend caution about relying on TSH alone when a patient is taking a T3-containing product.

Plausible but not firmly established at the level of precise numbers: Specific percentage differences in free T3 between NDT and levothyroxine patients at matched TSH, specific hazard ratios for atrial fibrillation or fracture tied to a given TSH threshold, and the degree of benefit from split-dosing all appear in the literature in some form, but the exact figures require verification against the primary papers before being quoted to a patient or used to justify a dosing decision. Readers and clinicians should treat any precise percentage or fold-risk number in older popular writeups on this topic, including earlier versions of this page, as needing a direct source check.

Not established: That a suppressed TSH with a normal free T3 is always safe, or always evidence of overtreatment. Individual cardiac and bone risk varies, and age, cardiac history, and menopausal status change the acceptable range.

Baseline labs before starting Armour Thyroid

Before the first dose, a baseline thyroid panel gives a reference point for later comparisons. A reasonable baseline includes TSH, free T4, free T3, and thyroid peroxidase (TPO) antibodies, since autoimmune thyroiditis can make dosing less stable over time. Many clinicians also check a lipid panel at baseline, since untreated hypothyroidism can raise LDL cholesterol, and a complete blood count, since hypothyroidism is associated with macrocytic anemia in some patients.

For patients over 60, or with known cardiac disease, a baseline ECG is a reasonable addition before starting a T3-containing product, given that T3 can increase heart rate more than T4-only therapy in some patients. Recording resting heart rate, blood pressure, weight, and a structured symptom checklist at the first visit gives something concrete to compare against later, especially in situations where labs and symptoms disagree.

The 6-week recheck: why this interval and not sooner

A repeat TSH, free T4, and free T3 roughly six weeks after starting Armour Thyroid, or after any dose change, is a common and reasonable interval. TSH takes time to reach a new steady state after a dose change because of T4's multi-day half-life, so checking earlier than several weeks out risks acting on a number that has not settled yet.

Timing of the blood draw matters as much as the interval. Blood should be drawn fasting, before that day's Armour dose, roughly a day after the last dose. T3 has a short half-life and produces a temporary peak in free T3 within a few hours of ingestion; a sample drawn after that morning's dose can look artificially high and lead to an unnecessary dose reduction. If a patient mistakenly takes their dose before a lab draw, that should be documented and the free T3 result treated as uninterpretable for dosing purposes rather than acted on.

Should you treat a low TSH as overtreatment?

Not automatically. Because T3 suppresses pituitary TSH release more efficiently than T4 does, a TSH modestly below the standard reference range can occur in a patient on Armour who is not clinically overtreated, provided free T3 is not elevated and the patient has no symptoms of excess thyroid hormone. This is a recognized feature of combination T4/T3 therapy in ATA guidance, though the guidance stops short of endorsing a fixed "safe" TSH floor for every patient.

Age and cardiac risk change the calculus. Observational cohort data going back decades has linked a persistently low TSH (subclinical hyperthyroidism) in older adults to a higher rate of atrial fibrillation over long follow-up; the exact magnitude reported in any single cohort should be checked against the original paper before it is repeated as a precise number, but the direction of the association is consistent enough that most guidelines advise avoiding sustained TSH suppression in people over 60 or with cardiovascular risk factors. A TSH clearly below the lower limit of normal, together with a high free T3 or a resting heart rate consistently above roughly 90 beats per minute, is a more concrete signal to reduce the dose than a mildly low TSH by itself.

Ongoing monitoring once the dose is stable

Once symptoms have resolved and labs are stable across at least one recheck, most patients can move to monitoring every 6 to 12 months rather than every 6 weeks. Each visit should still include TSH, free T4, and free T3, plus a check of resting heart rate, weight, and symptoms. An annual visit is a reasonable time to add a lipid panel and to reconsider bone density screening in patients who run a persistently low TSH.

Certain events should reset the clock back to a 6-week recheck: any dose change, pregnancy, starting or stopping estrogen therapy (which raises thyroxine-binding globulin and changes free hormone availability), starting or stopping medications that interfere with absorption or clearance, a large unintentional weight change, or new symptoms suggesting under- or overtreatment.

Medications that change the monitoring picture

Several common drugs interact with thyroid hormone handling in ways that justify an earlier-than-scheduled recheck:

• Calcium carbonate, iron supplements, and aluminum-containing antacids can bind thyroid hormone in the gut; separating doses by several hours is a common recommendation, and a recheck is reasonable if one of these is newly started.
• Estrogen-containing contraceptives and hormone therapy increase thyroxine-binding globulin, which can reduce free hormone availability and increase the dose a patient needs.
• Enzyme-inducing drugs, and amiodarone (which carries a large iodine load and can push thyroid function in either direction), both warrant closer-than-usual thyroid monitoring while they are being started or adjusted.

Anyone starting or stopping one of these medications should discuss the timing of the next thyroid recheck with their prescriber rather than waiting for the routine interval.

Pregnancy, older adults, and cardiac disease

Pregnancy calls for closer monitoring than the standard schedule because thyroid hormone requirements typically rise, particularly in the first half of pregnancy. ATA guidance on thyroid disease in pregnancy recommends more frequent TSH checks through the first and into the second trimester, with trimester-specific target ranges that are tighter than the general adult range. Some clinicians switch patients from a T3-containing product to levothyroxine monotherapy during pregnancy because T3 crosses the placenta less efficiently than T4; whether to switch is an individual decision between patient and prescriber, not a fixed rule for every pregnant patient on NDT.

In patients over 65, or those with coronary artery disease, a more conservative titration pace and closer cardiac monitoring, including resting heart rate at every visit and periodic ECGs, is a reasonable precaution given the T3 bolus effect. New chest pain, shortness of breath, palpitations, or an irregular pulse in a patient on Armour Thyroid warrants prompt medical evaluation rather than waiting for the next scheduled lab draw.

When to seek care sooner than the next scheduled visit

Contact the prescribing clinician or seek urgent care for a racing or irregular heartbeat, chest pain, unexplained significant weight loss, tremor, heat intolerance, or agitation that could reflect overtreatment, or for new severe fatigue, unexplained weight gain, cold intolerance, or constipation that could reflect undertreatment. These symptom changes should not wait for the next routine 6-month or annual lab draw.

Monitoring decision framework: matching the lab pattern to the next step

This table is an organizing framework for discussion with a prescriber, not a substitute for individualized dosing advice.

The two failure modes this table is meant to prevent: reducing a dose because TSH alone looks low while free T3 and symptoms are actually fine, and dismissing real undertreatment symptoms because a single TSH value falls inside the standard reference range.

Frequently asked questions

A note on sourcing

Several numeric claims that commonly circulate about desiccated thyroid monitoring, including specific percentage differences between NDT and levothyroxine, specific fold-increases in cardiovascular or fracture risk tied to a given TSH cutoff, and the magnitude of benefit from split dosing, could not be independently verified against a specific primary paper for this draft. Where a precise number could not be confirmed, this article has been written to describe the general direction of the evidence and flag that exact figures should be checked against the original study before being used in patient counseling or shared elsewhere. General guideline positions (ATA guidelines on hypothyroidism treatment and on thyroid disease in pregnancy, and AACE/ACE clinical practice guidance on hypothyroidism) support the overall monitoring framework described here, but this article does not link to specific journal identifiers that could not be verified as accurate for the claims attached to them.